Retatrutide
Contents
What is Retatrutide?
Retatrutide is an investigational triple hormone receptor agonist – a single medication that mimics the action of three key metabolic hormones: GLP-1, GIP, and glucagon. By targeting all three of these pathways at once, retatrutide represents a next-generation approach in treating type 2 diabetes and obesity. In this article, we explain what GLP-1, GIP, and glucagon do, how retatrutide works, and highlight major findings from recent research studies.
What are GLP-1 and GIP?
Glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut (specifically by intestinal L-cells) in response to eating. It has several important roles in metabolism and appetite regulation:
- GLP-1 stimulates insulin release from the pancreas when blood sugar is high, helping lower blood glucose levels.
- At the same time, it reduces the release of glucagon from the pancreas, a hormone that normally signals the liver to put more sugar into the bloodstream.
- GLP-1 also slows down stomach emptying, meaning food is digested more slowly and glucose from meals enters the bloodstream gradually.
- In addition, GLP-1 acts on the brain to increase feelings of fullness (satiety) and reduce appetite after eating.
Through these combined actions, our natural GLP-1 hormone helps keep blood sugar in check and tells us to eat less, especially after meals. However, in conditions like type 2 diabetes, the GLP-1 response may be blunted or insufficient.
GIP (Glucose-Dependent Insulinotropic Polypeptide) is the other major “incretin” hormone from the gut, secreted by K-cells in the small intestine when we eat. Like GLP-1, GIP has important metabolic roles:
- It stimulates insulin secretion in a glucose-dependent manner (meaning it mainly works when blood sugar is elevated). In fact, GIP typically accounts for a large portion of the insulin released after meals in healthy people. However, in people with type 2 diabetes, the insulin-releasing effect of GIP is often impaired.
- Unlike GLP-1, GIP by itself has little effect on appetite – GLP-1 greatly reduces appetite and food intake, whereas GIP alone has not shown significant impact on food intake.
Glucagon: Glucagon is a hormone made by pancreatic alpha cells that essentially does the opposite of insulin
- When blood sugar is low (for example, between meals), glucagon signals the liver to release stored glucose, raising blood sugar levels. It’s not considered an incretin (since it’s not secreted from the gut in response to food), but it plays a key role in overall glucose balance
- Besides raising glucose, glucagon increases the breakdown of fats and can boost energy expenditure (calorie burning) by activating brown fat and other pathways. It also tends to reduce appetite via effects on the brain and liver signals.
In the context of a combined therapy like retatrutide, the GLP-1 and GIP effects ensure that blood sugar is controlled (by insulin release and slowed gastric emptying), while the glucagon receptor activation adds an extra push for burning calories and fat. In short, glucagon in this “triple agonist” acts to further enhance weight loss in the research setting, while the incretins handle glucose control.
How Does Retatrutide Work?
Retatrutide is often described as a “triple-incretin” or “tri-agonist” therapy because it stimulates three hormone receptors at once. Specifically, it binds to and activates the receptors for GLP-1, GIP, and glucagon. By engaging all three pathways simultaneously, retatrutide amplifies the metabolic effects that each hormone has on its own.
- Boosted insulin and lower blood sugar: GLP-1 and GIP together markedly enhance insulin secretion when glucose is high, while GLP-1 also curbs the liver’s glucagon output. Even though retatrutide activates the glucagon receptor, the net effect in diabetics is a drop in blood sugar because the incretin effects (more insulin, slower gastric emptying) dominate. In fact, retatrutide showed greater glucose-lowering in research trials than a traditional GLP-1 agonist alone.
- Increased energy expenditure and fat burn: The glucagon receptor activation sets retatrutide apart from “dual” incretin drugs (e.g. tirzepatide). In research studies, the glucagon agonism in retatrutide appears to increase caloric burn and fat metabolism beyond what GLP-1/GIP alone would do. This means the body may be shifting into a higher gear for burning stored fat, contributing to the larger weight reductions observed. Researchers have noted that retatrutide’s triple-action led to unprecedented weight loss in trials, supporting the idea of synergy between these hormone pathways.
In summary, retatrutide works by simultaneously improving insulin action, curbing appetite, and increasing energy expenditure. It’s essentially combining the proven benefits of GLP-1 agonists (like semaglutide), the added insulin boost of GIP, and the fat-burning potential of glucagon agonism in one therapy – a strategy that early studies suggest may be extraordinarily effective for both blood sugar control and weight loss.
Clinical Uses of Retatrutide
- Obesity and Weight Management: The most prominent potential use of retatrutide is in treating obesity. In a 48-week phase 2 trial with adults having obesity (or overweight with complications), retatrutide showed dramatic weight loss effects. Patients on the highest dose (12 mg weekly) lost around 24% of their body weight on average in 48 weeks, compared to only ~2% weight loss in the placebo group.
- Type 2 Diabetes Mellitus (T2DM): Retatrutide was also designed to treat type 2 diabetes, given its robust glucose-lowering mechanisms. In a phase 2 study in people with T2DM (who were overweight and mostly on metformin alone), retatrutide achieved striking improvements in blood sugar control. At 24 weeks, high-dose retatrutide lowered hemoglobin A1c (a 3-month blood sugar average) by up to 2.0 percentage points from baseline, versus a ~1.4% drop with a standard GLP-1 drug (dulaglutide) and essentially no change on placebo. By 36 weeks, patients on retatrutide had continued to improve or maintain these gains, and they also lost significant weight: up to ~17% body weight reduction at the higher doses, compared to ~2–3% with placebo or dulaglutide. These results suggest retatrutide could offer a two-fold benefit for diabetics: better blood sugar and substantial weight loss.
Side Effects of Retatrutide
Like other medications that activate GLP-1 receptors, retatrutide can cause gastrointestinal side effects in a significant number of patients. In clinical trials, the most common adverse events were nausea, vomiting, diarrhea, and constipation – typical for GLP-1 analogs. These side effects were generally mild to moderate and tended to occur during the initial dose-escalation phase when the body is adjusting. The glucagon component may contribute to GI effects because glucagon itself can slow stomach emptying and affect gut motility, compounding GLP-1’s effects.
Safety considerations: Retatrutide use comes with a warning (similar to other GLP-1 agonists) about a potential risk of thyroid C-cell tumors. This is based on rodent studies in which extremely high doses caused a specific type of thyroid tumor. No cases of this cancer have been seen in human trials, but as a precaution, retatrutide is not given to patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome.
Retatrutide Dosing Protocol (for Research)
Retatrutide is still in clinical trials, and the ideal dosing regimen has not yet been established. Hence, researchers differ in their exact dosing protocols. Below is one of the most common
- 1Weeks 1-4: 1.5 mg once weekly
- 2Week 5-8: 3 mg once weekly
- 3Week 9-12: 6 mg once weekly
- 4Week 13 -16: 8 mg once weekly
- 5Week 17-20: 10 mg once weekly
- 6Week 20 and beyond: 12 mg once weekly
- Note: Titrating to the maximum dose is not required to achieve intended research outcomes.
Recommended Retatrutide Source (for Research)